{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T12:04:21Z","timestamp":1764072261681,"version":"3.45.0"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"19","license":[{"start":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T00:00:00Z","timestamp":1715299200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,5,10]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Systemic therapy is recommended for patients with advanced hepatocellular carcinoma (aHCC). However, drug resistance occurs over time when patients receive systemic therapy, resulting in cancer progression. Due to the lack of relevant clinical trials, optimizing subsequent treatments after cancer progression remains elusive.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient concerns:<\/jats:title>\n                    <jats:p>A 52-year-old male patient presented with epigastric discomfort and fatigue for almost 1 month with a past history of chronic hepatitis B virus infection for 30 years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnosis:<\/jats:title>\n                    <jats:p>Based on the patient\u2019s performance status, tumor status assessed by computed tomography, liver function, he was diagnosed with HCC at BCLC stage C.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions and Outcomes:<\/jats:title>\n                    <jats:p>He first received transarterial chemoembolization (TACE) combined with sintilimab and lenvatinib as first-line treatment and experienced 10-month progression-free survival. After cancer progression, the patient participated in a clinical trial of ABSK-011, a novel fibroblast growth factor receptor 4 inhibitor, with a frustrating result. Then, the patient underwent TACE and received sintilimab plus lenvatinib again. Surprisingly, the tumor had a partial response, and the patient\u2019s serum alpha-fetoprotein returned to normal.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lessons:<\/jats:title>\n                    <jats:p>The combined treatment of TACE plus systemic therapy might be an appropriate subsequent treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000038138","type":"journal-article","created":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T14:01:25Z","timestamp":1715349685000},"page":"e38138","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Improvements in advanced hepatocellular carcinoma to repeat implementation of primary protocol after cancer progression occurs following sequential systemic therapy and a clinical trial: A case report"],"prefix":"10.1097","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-9741-5901","authenticated-orcid":false,"given":"Hongwei","family":"Huang","sequence":"first","affiliation":[{"name":"Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiaoqiao","family":"Wei","sequence":"additional","affiliation":[{"name":"Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Leng","sequence":"additional","affiliation":[{"name":"Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Wang","sequence":"additional","affiliation":[{"name":"Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Mei","sequence":"additional","affiliation":[{"name":"Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20251125","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 Cancers in 185 Countries.","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R2-20251125","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1111\/liv.12818","article-title":"Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study.","volume":"35","author":"Park","year":"2015","journal-title":"Liver Int"},{"key":"R3-20251125","doi-asserted-by":"crossref","first-page":"4317","DOI":"10.1200\/JCO.20.02672","article-title":"Systemic therapy for advanced hepatocellular carcinoma: ASCO Guideline.","volume":"38","author":"Gordan","year":"2020","journal-title":"J Clin Oncol"},{"key":"R4-20251125","doi-asserted-by":"crossref","first-page":"848387","DOI":"10.3389\/fimmu.2022.848387","article-title":"Transarterial chemoembolization combined with lenvatinib plus PD-1 inhibitor for advanced hepatocellular carcinoma: a retrospective cohort study.","volume":"13","author":"Cai","year":"2022","journal-title":"Front Immunol"},{"key":"R5-20251125","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2217\/imt-2021-0057","article-title":"Optimal subsequent treatments for patients with hepatocellular carcinoma resistant to anti-PD-1 treatment.","volume":"14","author":"Sun","year":"2021","journal-title":"Immunotherapy"},{"key":"R6-20251125","doi-asserted-by":"crossref","first-page":"e001945","DOI":"10.1136\/jitc-2020-001945","article-title":"Ipilimumab and nivolumab\/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors.","volume":"9","author":"Wong","year":"2021","journal-title":"J ImmunoTher Cancer"},{"key":"R7-20251125","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","article-title":"Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.","volume":"22","author":"Ren","year":"2021","journal-title":"Lancet Oncol"},{"key":"R8-20251125","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"\u201cEASL clinical practice guidelines: management of hepatocellular carcinoma.\u201d.","volume":"69","year":"2018","journal-title":"J Hepatol"},{"key":"R9-20251125","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1200\/JCO.22.00392","article-title":"Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma: a Phase III, Randomized Clinical Trial (LAUNCH).","volume":"41","author":"Peng","year":"2023","journal-title":"J Clin Oncol"},{"key":"R10-20251125","doi-asserted-by":"crossref","first-page":"783480","DOI":"10.3389\/fonc.2021.783480","article-title":"The Efficacy of TACE combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma: a multicenter retrospective study.","volume":"11","author":"Cao","year":"2021","journal-title":"Front Oncol"},{"key":"R11-20251125","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/s41575-021-00438-0","article-title":"Advances in immunotherapy for hepatocellular carcinoma.","volume":"18","author":"Sangro","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R12-20251125","doi-asserted-by":"crossref","first-page":"e0212513","DOI":"10.1371\/journal.pone.0212513","article-title":"Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway.","volume":"14","author":"Kato","year":"2019","journal-title":"PLoS One"},{"key":"R13-20251125","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1126\/science.1104819","article-title":"Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy.","volume":"307","author":"Jain","year":"2005","journal-title":"Science"},{"key":"R14-20251125","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/s41586-021-03741-7","article-title":"EGFR activation limits the response of liver cancer to lenvatinib.","volume":"595","author":"Jin","year":"2021","journal-title":"Nature"},{"key":"R15-20251125","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1159\/000504624","article-title":"Effects of subsequent systemic anticancer medication following first-line lenvatinib: a post hoc responder analysis from the phase 3 REFLECT study in unresectable hepatocellular carcinoma.","volume":"9","author":"Alsina","year":"2020","journal-title":"Liver Cancer"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000038138","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T12:00:59Z","timestamp":1764072059000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000038138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,10]]},"references-count":15,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000038138","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"type":"print","value":"0025-7974"},{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2024,5,10]]}}}